Home › NDC Lookup › RxCUI directory › RxCUI 2594747

{7 (mitapivat 20 MG Oral Tablet) / 7 (mitapivat 5 MG Oral Tablet) } Pack — RxCUI 2594747

RxNorm drug concept · Generic pack
RxCUI 2594747 Generic pack · GPCK ● Current RxNorm concept 6 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2594747
Official name{7 (mitapivat 20 MG Oral Tablet) / 7 (mitapivat 5 MG Oral Tablet) } Pack
Concept typeGeneric pack (GPCK)
RxNorm statusCurrent RxNorm concept
Also known asmitapivat 5 MG / 20 MG Taper Pack
FDA products mapped6
Package NDCs mapped6
Reported Medicaid activity (SDUD)125 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Mitapivat: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • That depends on which brand you've been prescribed. If you're taking Pyrukynd, it's treating the underlying cause of your anemia from PK deficiency — it boosts a faulty enzyme in y...
  • What exactly is mitapivat supposed to do for me?
  • It really depends on which product you're on. If you're taking Pyrukynd, you should never stop it abruptly — stopping suddenly can trigger a rapid and dangerous breakdown of your r...
  • Can I just stop taking it if I feel fine or if a side effect bothers me?
📖 Read our full Mitapivat guide →

🕸️ Concept Web — How {7 (mitapivat 20 MG Oral Tablet) / 7 (mitapivat... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept {7 (mitapivat 20 MG Oral Tablet) / 7 (mitapivat 5 MG Oral Tablet) } Pack RxCUI 2594747

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Mitapivat 2594468
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Pyrukynd 2594474
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Mitapivat Oral Tablet 2594472
    • Mitapivat Oral Product 2594470
    • Mitapivat Pill 2594471
    • Mitapivat Oral Tablet [Pyrukynd] 2594478
    • Pyrukynd Oral Product 2594476
    • Pyrukynd Pill 2594477
    • Pack 746839
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 8

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 1

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 19 of 20 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

📦 FDA Products & Package NDCs

6 products · 6 package NDCs
6 package NDCs map to RxCUI 2594747 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
71334-0205-05 4 BLISTER PACK in 1 CARTON (71334-205-05) / 14 TABLET, FILM... PYRUKYND Agios Pharmaceuticals, Inc. 2022-02-18
71334-0210-20 4 BLISTER PACK in 1 CARTON (71334-210-20) / 14 TABLET, FILM... PYRUKYND Agios Pharmaceuticals, Inc. 2022-02-18
71334-0215-50 4 BLISTER PACK in 1 CARTON (71334-215-50) / 14 TABLET, FILM... PYRUKYND Agios Pharmaceuticals, Inc. 2022-02-18
71334-0220-11 1 BLISTER PACK in 1 CARTON (71334-220-11) / 7 TABLET, FILM... PYRUKYND Agios Pharmaceuticals, Inc. 2022-02-18
71334-0225-12 1 KIT in 1 CARTON (71334-225-12) * 7 TABLET, FILM COATED i... PYRUKYND Agios Pharmaceuticals, Inc. 2022-02-18
71334-0230-13 1 KIT in 1 CARTON (71334-230-13) * 7 TABLET, FILM COATED i... PYRUKYND Agios Pharmaceuticals, Inc. 2022-02-18
Observed labelers: Agios Pharmaceuticals, Inc. (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.